Logo image of ERAS

ERASCA INC (ERAS) Stock Fundamental Analysis

USA - NASDAQ:ERAS - US29479A1088 - Common Stock

2.25 USD
-0.02 (-0.88%)
Last: 10/23/2025, 11:20:06 AM
Fundamental Rating

3

Taking everything into account, ERAS scores 3 out of 10 in our fundamental rating. ERAS was compared to 534 industry peers in the Biotechnology industry. While ERAS has a great health rating, there are worries on its profitability. ERAS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ERAS has reported negative net income.
In the past year ERAS has reported a negative cash flow from operations.
In the past 5 years ERAS always reported negative net income.
In the past 5 years ERAS always reported negative operating cash flow.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ERAS has a better Return On Assets (-28.80%) than 68.54% of its industry peers.
With a decent Return On Equity value of -34.46%, ERAS is doing good in the industry, outperforming 75.09% of the companies in the same industry.
Industry RankSector Rank
ROA -28.8%
ROE -34.46%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ERAS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ERAS has been increased compared to 1 year ago.
Compared to 5 years ago, ERAS has more shares outstanding
There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.40 indicates that ERAS is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ERAS (2.40) is better than 66.10% of its industry peers.
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.4
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ERAS has a Current Ratio of 11.04. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
ERAS has a better Current ratio (11.04) than 83.33% of its industry peers.
A Quick Ratio of 11.04 indicates that ERAS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 11.04, ERAS belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.04
Quick Ratio 11.04
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ERAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.09%, which is quite impressive.
EPS 1Y (TTM)51.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ERAS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.22% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.15%
EPS Next 2Y16.87%
EPS Next 3Y10.01%
EPS Next 5Y12.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERAS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.87%
EPS Next 3Y10.01%

More info and screens

0

5. Dividend

5.1 Amount

ERAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERASCA INC

NASDAQ:ERAS (10/23/2025, 11:20:06 AM)

2.25

-0.02 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners73.92%
Inst Owner Change-0.01%
Ins Owners7.34%
Ins Owner Change0%
Market Cap638.26M
Revenue(TTM)N/A
Net Income(TTM)-128274000
Analysts80
Price Target5.1 (126.67%)
Short Float %8.17%
Short Ratio18.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.73%
Min EPS beat(2)-6.95%
Max EPS beat(2)14.41%
EPS beat(4)3
Avg EPS beat(4)13.95%
Min EPS beat(4)-6.95%
Max EPS beat(4)35.3%
EPS beat(8)5
Avg EPS beat(8)1.58%
EPS beat(12)8
Avg EPS beat(12)-13.31%
EPS beat(16)10
Avg EPS beat(16)-10.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0.52%
EPS NQ rev (3m)9.78%
EPS NY rev (1m)0.64%
EPS NY rev (3m)4.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.8%
ROE -34.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.04
Quick Ratio 11.04
Altman-Z 2.4
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.09%
Cap/Depr(5y)425.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.62%
EPS Next Y39.15%
EPS Next 2Y16.87%
EPS Next 3Y10.01%
EPS Next 5Y12.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.82%
EBIT Next 3Y2.17%
EBIT Next 5Y1.37%
FCF growth 1Y7.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.46%
OCF growth 3YN/A
OCF growth 5YN/A